Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: GOLGB1

Gene summary for GOLGB1

Gene summary.

Gene information	Species	Human
	Gene symbol	GOLGB1
	Gene ID	2804
	Gene name	golgin B1
	Gene Alias	GCP
	Cytomap	3q13.33
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	Q14789

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2804	GOLGB1	GSM4909293	Human	Breast	IDC	2.19e-11	4.12e-01	0.1581
2804	GOLGB1	GSM4909296	Human	Breast	IDC	1.06e-08	-2.96e-01	0.1524
2804	GOLGB1	GSM4909297	Human	Breast	IDC	7.43e-10	-2.64e-01	0.1517
2804	GOLGB1	GSM4909311	Human	Breast	IDC	1.54e-24	-2.24e-01	0.1534
2804	GOLGB1	GSM4909312	Human	Breast	IDC	2.88e-08	-2.84e-01	0.1552
2804	GOLGB1	GSM4909317	Human	Breast	IDC	6.56e-16	5.68e-01	0.1355
2804	GOLGB1	GSM4909319	Human	Breast	IDC	1.12e-28	-3.06e-01	0.1563
2804	GOLGB1	GSM4909321	Human	Breast	IDC	2.26e-14	-2.66e-01	0.1559
2804	GOLGB1	M2	Human	Breast	IDC	1.67e-03	1.98e-01	0.21
2804	GOLGB1	NCCBC14	Human	Breast	DCIS	2.52e-11	2.21e-02	0.2021
2804	GOLGB1	NCCBC2	Human	Breast	DCIS	4.07e-02	1.23e-01	0.1554
2804	GOLGB1	NCCBC3	Human	Breast	DCIS	1.63e-04	2.73e-01	0.1198
2804	GOLGB1	NCCBC5	Human	Breast	DCIS	3.24e-08	-1.92e-01	0.2046
2804	GOLGB1	P1	Human	Breast	IDC	2.94e-11	3.44e-02	0.1527
2804	GOLGB1	P2	Human	Breast	IDC	2.55e-04	2.66e-01	0.21
2804	GOLGB1	DCIS2	Human	Breast	DCIS	1.05e-62	7.40e-01	0.0085
2804	GOLGB1	CA_HPV_1	Human	Cervix	CC	3.23e-06	-2.30e-01	0.0264
2804	GOLGB1	CA_HPV_3	Human	Cervix	CC	2.24e-02	8.66e-02	0.0414
2804	GOLGB1	HSIL_HPV_1	Human	Cervix	HSIL_HPV	3.68e-02	-2.90e-01	0.0116
2804	GOLGB1	CCI_1	Human	Cervix	CC	1.99e-02	5.47e-01	0.528

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00070304	Cervix	CC	Golgi organization	32/2311	157/18723	2.78e-03	1.87e-02	32
GO:0071539	Colorectum	AD	protein localization to centrosome	16/3918	33/18723	3.86e-04	4.41e-03	16
GO:1905508	Colorectum	AD	protein localization to microtubule organizing center	16/3918	35/18723	8.76e-04	8.51e-03	16
GO:00715391	Colorectum	MSS	protein localization to centrosome	16/3467	33/18723	8.66e-05	1.40e-03	16
GO:19055081	Colorectum	MSS	protein localization to microtubule organizing center	16/3467	35/18723	2.07e-04	2.89e-03	16
GO:0044380	Colorectum	MSS	protein localization to cytoskeleton	19/3467	58/18723	6.69e-03	4.38e-02	19
GO:0072698	Colorectum	MSS	protein localization to microtubule cytoskeleton	18/3467	54/18723	6.70e-03	4.38e-02	18
GO:00715392	Colorectum	FAP	protein localization to centrosome	14/2622	33/18723	6.39e-05	1.23e-03	14
GO:19055082	Colorectum	FAP	protein localization to microtubule organizing center	14/2622	35/18723	1.38e-04	2.18e-03	14
GO:00726981	Colorectum	FAP	protein localization to microtubule cytoskeleton	16/2622	54/18723	2.26e-03	1.84e-02	16
GO:00443801	Colorectum	FAP	protein localization to cytoskeleton	16/2622	58/18723	4.97e-03	3.32e-02	16
GO:00715393	Colorectum	CRC	protein localization to centrosome	11/2078	33/18723	5.80e-04	7.89e-03	11
GO:19055083	Colorectum	CRC	protein localization to microtubule organizing center	11/2078	35/18723	1.02e-03	1.20e-02	11
GO:00726982	Colorectum	CRC	protein localization to microtubule cytoskeleton	13/2078	54/18723	5.25e-03	3.98e-02	13
GO:00070305	Endometrium	AEH	Golgi organization	32/2100	157/18723	5.73e-04	5.69e-03	32
GO:000703012	Endometrium	EEC	Golgi organization	32/2168	157/18723	9.87e-04	8.76e-03	32
GO:00726985	Esophagus	ESCC	protein localization to microtubule cytoskeleton	43/8552	54/18723	3.28e-07	4.61e-06	43
GO:00443804	Esophagus	ESCC	protein localization to cytoskeleton	45/8552	58/18723	6.89e-07	8.99e-06	45
GO:00070308	Esophagus	ESCC	Golgi organization	101/8552	157/18723	1.78e-06	2.10e-05	101
GO:19055086	Esophagus	ESCC	protein localization to microtubule organizing center	28/8552	35/18723	3.40e-05	2.78e-04	28

Page: 1 2 3

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

GOLGB1

SNV

Missense_Mutation

rs761066625

c.4366G>A

p.Asp1456Asn

p.D1456N

Q14789

protein_coding

deleterious(0.03)

benign(0.001)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

GOLGB1

SNV

Missense_Mutation

c.4128N>T

p.Gln1376His

p.Q1376H

Q14789

protein_coding

deleterious(0.02)

benign(0.179)

TCGA-A2-A0CV-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

GOLGB1

SNV

Missense_Mutation

c.6727N>A

p.Asp2243Asn

p.D2243N

Q14789

protein_coding

tolerated(0.07)

benign(0.368)

TCGA-A8-A08B-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

GOLGB1

SNV

Missense_Mutation

rs762656767

c.4117N>A

p.Glu1373Lys

p.E1373K

Q14789

protein_coding

tolerated(0.14)

benign(0.028)

TCGA-A8-A0A1-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

GOLGB1

SNV

Missense_Mutation

c.7588N>C

p.Glu2530Gln

p.E2530Q

Q14789

protein_coding

tolerated(0.06)

probably_damaging(0.997)

TCGA-AC-A23C-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

chemo

GOLGB1

SNV

Missense_Mutation

c.7567N>T

p.His2523Tyr

p.H2523Y

Q14789

protein_coding

deleterious(0.01)

benign(0.439)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GOLGB1

SNV

Missense_Mutation

c.3712N>G

p.Leu1238Val

p.L1238V

Q14789

protein_coding

deleterious(0)

benign(0.25)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GOLGB1

SNV

Missense_Mutation

c.1717N>C

p.Glu573Gln

p.E573Q

Q14789

protein_coding

tolerated(0.09)

probably_damaging(0.997)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GOLGB1

SNV

Missense_Mutation

novel

c.7803N>T

p.Glu2601Asp

p.E2601D

Q14789

protein_coding

tolerated(0.79)

benign(0.024)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GOLGB1

SNV

Missense_Mutation

novel

c.5892N>T

p.Lys1964Asn

p.K1964N

Q14789

protein_coding

deleterious(0)

benign(0.036)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1